LSDIF (Lucy Scientific Discovery) Current Ratio: 0.38 (As of Dec. 2023)


What is Lucy Scientific Discovery Current Ratio?

Lucy Scientific Discovery LSDIF Current Ratio is 0.38 as of Dec. 2023.

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Lucy Scientific Discovery's current ratio for the quarter that ended in Dec. 2023 was 0.38.

Lucy Scientific Discovery has a current ratio of 0.38. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Lucy Scientific Discovery has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for Lucy Scientific Discovery's Current Ratio or its related term are showing as below:

LSDIF's Current Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.995
* Ranked among companies with meaningful Current Ratio only.

Lucy Scientific Discovery  (OTCPK:LSDIF) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Lucy Scientific Discovery Current Ratio Related Terms


Lucy Scientific Discovery Current Ratio Historical Data

* Premium members only.

The historical data trend for Lucy Scientific Discovery's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lucy Scientific Discovery Current Ratio Chart

Lucy Scientific Discovery Annual Data
Trend Jun21 Jun22 Jun23
Current Ratio
0.42 0.33 1.41

Lucy Scientific Discovery Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.17 2.80 1.41 0.71 0.38

LSDIF vs INQD, ZTS, VTRS: Current Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lucy Scientific Discovery's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lucy Scientific Discovery Current Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lucy Scientific Discovery's Current Ratio distribution charts can be found below:

* The bar in red indicates where Lucy Scientific Discovery's Current Ratio falls into.



Lucy Scientific Discovery Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Lucy Scientific Discovery's Current Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Current Ratio (A: Jun. 2023 )=Total Current Assets (A: Jun. 2023 )/Total Current Liabilities (A: Jun. 2023 )
=3.822/2.71
=1.41

Lucy Scientific Discovery's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=1.338/3.487
=0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Current Ratio →
What does a Current Ratio of 0.38 mean?
Lucy Scientific Discovery (LSDIF) has a Current Ratio of 0.38 as of Dec. 2023.
Is Lucy Scientific Discovery's Current Ratio too high?
Lucy Scientific Discovery's current Current Ratio is 0.38. The Drug Manufacturers industry median Current Ratio is 2.00. Lucy Scientific Discovery's value of 0.38 is 81% below this industry median.
How does Lucy Scientific Discovery's Current Ratio compare to INQD and ZTS?
Lucy Scientific Discovery's Current Ratio of 0.38 can be compared against companies in the Drug Manufacturers industry. The industry median Current Ratio is 2.00. Lucy Scientific Discovery's value of 0.38 is 81% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lucy Scientific Discovery's current Current Ratio of 0.38 is 81% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lucy Scientific Discovery's current Current Ratio is 0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucy Scientific Discovery stock overvalued right now?
Lucy Scientific Discovery (LSDIF) has a current Current Ratio of 0.38. The current Current Ratio is 0.38 and 81% below the Drug Manufacturers industry median of 2.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Lucy Scientific Discovery (LSDIF), the current Current Ratio is 0.38 as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lucy Scientific Discovery Business Description

Address 301-1321 Blanshard Street, Victoria, BC, CAN, V8W 0B6
Lucy Scientific Discovery Inc is an early-stage psychotropics contract manufacturing company focused on becoming the contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry. Its drug products are designed to treat a range of mental health and cognitive conditions.